Literature DB >> 20832141

[Preservatives in eye drops: toward awareness of their toxicity].

D Vaede1, C Baudouin, J-M Warnet, F Brignole-Baudouin.   

Abstract

Preservatives are present in numerous multidose eyedrops and provide the sterility of the solution against bacteria and fungi. However, numerous studies have shown their toxicity for the ocular surface, particularly in long-term treatments. The most widely used preservative in eyedrops is benzalkonium chloride. This quaternary ammonium acts as a detergent, antiseptic, disinfectant, fungicide, bactericide, and spermicide. Its use on the ocular surface therefore has significant consequences. Indeed, the preservatives are pro-apoptotic, pro-inflammatory and they cause the dissolution of the lachrymal film. The prolonged administration of one or several eye drops containing preservatives induces changes in the superficial structures (conjunctiva, cornea) as well as in deeper structures (trabecula, lens). The least severe symptoms are irritation and discomfort, including sensation of a foreign body, itching, or burning sensations. However, more severe side effects have been described, such as chronic inflammation of variable intensity or the progressive development of fibrosis with higher risk of failure after glaucoma filtering surgery. Ideally, preservative-free eyedrops should be recommended, or at least a reduction of the number of instilled preserved eyedrops should be considered. All these strategies could increase patient comfort, quality of life, and compliance, with better outcome at the time of filtering surgery.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20832141     DOI: 10.1016/j.jfo.2010.06.018

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  11 in total

1.  Barriers to Glaucoma Medication Compliance Among Veterans: Dry Eye Symptoms and Anxiety Disorders.

Authors:  Jack Stringham; Noy Ashkenazy; Anat Galor; Sarah R Wellik
Journal:  Eye Contact Lens       Date:  2018-01       Impact factor: 2.018

2.  Injectable drug depot engineered to release multiple ophthalmic therapeutic agents with precise time profiles for postoperative treatment following ocular surgery.

Authors:  Maziar Mohammadi; Kisha Patel; Seyedeh P Alaie; Ron B Shmueli; Cagri G Besirli; Ronald G Larson; Jordan J Green
Journal:  Acta Biomater       Date:  2018-04-21       Impact factor: 8.947

3.  Risk Factors for Ocular Surface Disease in Tunisian Users of Preserved Antiglaucomatous Eye Drops.

Authors:  Houda Lajmi; Wassim Hmaied; Besma Ben Achour; Amin Zahaf
Journal:  J Curr Ophthalmol       Date:  2021-07-05

4.  The Ex Vivo Eye Irritation Test (EVEIT) in evaluation of artificial tears: Purite-preserved versus unpreserved eye drops.

Authors:  N Schrage; M Frentz; F Spoeler
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-05-15       Impact factor: 3.117

5.  Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost.

Authors:  Anton Hommer; Friedemann Kimmich
Journal:  Clin Ophthalmol       Date:  2011-05-17

6.  Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients.

Authors:  Wissam Georges El Hajj Moussa; Rebecca Georges Farhat; Joseph Claud Nehme; Marwan Antoun Sahyoun; Alexandre Raymond Schakal; Alexandre Edmond Jalkh; Mariana Pierre Abi Karam; Georges Georges Azar
Journal:  J Ophthalmol       Date:  2018-03-07       Impact factor: 1.909

7.  Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study.

Authors:  Lutz E Pillunat; Carl Erb; Auli Ropo; Friedemann Kimmich; Norbert Pfeiffer
Journal:  Clin Ophthalmol       Date:  2017-06-02

8.  Patient-Reported Nonadherence with Glaucoma Therapy.

Authors:  Christian Wolfram; Erik Stahlberg; Norbert Pfeiffer
Journal:  J Ocul Pharmacol Ther       Date:  2019-03-21       Impact factor: 2.671

9.  Eyelid Disorders in Ophthalmology Practice: Results from a Large International Epidemiological Study in Eleven Countries.

Authors:  Serge Doan; Zbigniew Zagórski; Jorge Palmares; Meltem Yağmur; Thomas Kaercher; José Manuel Benítez-Del-Castillo; Bart Van Dooren; Paul Jonckheere; Peter Koch Jensen; Dmitry Yurevich Maychuk; Pavlo Bezdetko
Journal:  Ophthalmol Ther       Date:  2020-07-01

10.  Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension.

Authors:  Ines Lanzl; Thomas Hamacher; Klaus Rosbach; Mohammed Osman Ramez; Robert Rothe; Eva Růžičková; Marta Karhanová; Friedemann Kimmich
Journal:  Clin Ophthalmol       Date:  2013-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.